에서 실시간으로 운영 중이에요! 자세히 알아보기

Merit Medical Systems

MMSI

시가총액 US$53.3억

89.20 USD

-0.37

0.41%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

프리마켓

시간외 거래

89.20

0.00

0%

1일

-0.41%

5일

1.77%

1개월

3.55%

3개월

18.07%

6개월

27.25%

연초 이후

3.18%

1년

10.38%

5년

28.88%

10년

277.97%

소개: Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.

직원 수: 7,500

건강관리 의료 장비 및 용품

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 51.9%

중립 44.4%

부정적 3.7%

Zacks Investment Research

Cancer Stocks to Consider as Oncology Innovation Accelerates

Oncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies.

Cancer Stocks to Consider as Oncology Innovation Accelerates

Merit Medical Systems to Announce Third Quarter 2026 Results on October 29, 2026

SOUTH JORDAN, Utah, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2026, after the close of the stock market on Thursday, October 29, 2026. Merit plans to hold its investor conference call on the same day (Thursday, October 29, 2026) at 4:30 p.m. Eastern (3:30 p.m. Central, 2:30 p.m. Mountain, and 1:30 p.m. Pacific).

Merit Medical Systems to Announce Third Quarter 2026 Results on October 29, 2026

Zacks Investment Research

HSIC or MMSI: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Henry Schein (HSIC) or Merit Medical (MMSI). But which of these two stocks presents investors with the better value opportunity right now?

HSIC or MMSI: Which Is the Better Value Stock Right Now?

Zacks Investment Research

Here's Why You Should Add Merit Medical Stock to Your Portfolio Now

MMSI's broad product portfolio, global expansion and strategic M&A support growth, while tariffs and China pressures remain key risks.

Here's Why You Should Add Merit Medical Stock to Your Portfolio Now

Zacks Investment Research

5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve

Here, we highlight five medical supplies stocks, MCK, CAH, BDX, MMSI and PDEX, with strong potential that investors should keep on their watchlist amid improving industry prospects.

5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve

Merit Medical to Participate in Upcoming Investors Conferences in September

SOUTH JORDAN, Utah, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that management is scheduled to participate in the following upcoming investor conferences:

Merit Medical to Participate in Upcoming Investors Conferences in September

Zacks Investment Research

Here's Why You Should Add Merit Medical Stock to Your Portfolio Now

MMSI's broad portfolio, R&D investments and WRAPSODY opportunity support growth, while tariffs, China pressure and competition remain risks.

Here's Why You Should Add Merit Medical Stock to Your Portfolio Now

Zacks Investment Research

Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves

Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.

Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves

Zacks Investment Research

Should You Buy MMSI as Growth Improves but Valuation Stays Elevated?

Merit Medical's growth case is strengthening as launches, acquisitions and therapeutic products broaden its mix, but its premium valuation raises the execution bar.

Should You Buy MMSI as Growth Improves but Valuation Stays Elevated?

Zacks Investment Research

Can MMSI Sustain Its 22.2% Gain in the Past Month as Growth Improves?

Merit Medical's 22.2% monthly rally gains support from stronger Q2 growth and a raised 2026 outlook, but valuation and tariff risks remain.

Can MMSI Sustain Its 22.2% Gain in the Past Month as Growth Improves?

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.